[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Rozenowicz Rde L, Santos RE, Silva MA, Rodrigues FF, Oliveira AL, Ulson LB, Oliveira VM, Aoki T: Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer. Rev Col Bras Cir; 2010 Oct;37(5):323-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer.
  • OBJECTIVE: To evaluate the immunohistochemical expression of cox-2 before primary chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and its association with initial tumor size, lymph node status, hormone receptors, expression of HER2 and the clinical and pathological response in patients with breast cancer.
  • METHODS: We conducted a retrospective study with 41 women with histopathological diagnosis of ductal breast carcinoma.
  • They underwent primary chemotherapy with FEC regimen (5-fluorouracil, epirubicin and cyclophosphamide) at 500mg/m2, 75mg/m2 and 500 mg/m2, respectively.
  • The evaluation of clinical response to treatment was performed during physical examination by measuring the major tumor axis with a pachymeter.
  • Measurements were taken at admission and after primary chemotherapy cycles.
  • After three chemotherapy sessions at intervals of 21 days the surgical procedure was carried out.
  • After the operation we evaluated the local pathological response, which was considered complete when there was absence of invasive neoplasia and of the in situ component.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Ductal, Breast / etiology. Cyclooxygenase 2 / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180996.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


2. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL: Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res; 2000 Aug;6(8):3342-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
  • Although chemotherapy-resistant tumors would be likely candidates for treatment with HSV-1 mutants lacking ICP34.5, the efficacy of these mutants on such tumors is unknown.
  • In the present study, we investigated whether chemotherapy resistance affects the response of ovarian cancer cells to HSV-R3616, an ICP34.5-deficient, replication-restricted HSV-1.
  • Primary EOC cultures obtained from patients who varied in their responses to platinum/paclitaxel induction chemotherapy displayed similar sensitivity to HSV-R3616.
  • Similarly, chemotherapy-sensitive ovarian cancer cells A2780 and PA-1, possessing wild-type p53, and their respective chemotherapy-resistant clones A2780/200CP, lacking p53 function, and PA-1/E6, permanently expressing the HPV E6 gene, were equally sensitive to HSV oncolysis.
  • Because wild-type HSV can kill cells by apoptosis and nonapoptotic mechanisms, we investigated the involvement of apoptosis and the role of the p53 tumor suppressor gene in oncolysis induced by HSV-R3616.
  • Infection of ovarian cancer cell lines by HSV-R3616 was followed by cell death via apoptosis or nonapoptotic mechanisms as noted by morphology, cell cycle analysis, and in situ TUNEL assay. p53 protein levels remained unchanged, and Bax protein levels decreased in cells possessing intact p53 and that mainly underwent HSV-induced apoptosis.
  • These results suggest that recombinant HSV-1 lacking ICP34.5 is capable of killing ovarian cancer cells that lack p53 function, resist apoptosis, and/or are chemotherapy resistant.
  • These data support the hypothesis that HSV-based oncolytic therapy may be efficacious in chemotherapy-resistant tumors, including tumors that are deficient in p53.
  • [MeSH-major] Herpesvirus 1, Human / physiology. Ovarian Neoplasms / therapy. Proto-Oncogene Proteins c-bcl-2. Tumor Suppressor Protein p53 / physiology. Viral Proteins / physiology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis / physiology. Cell Death / physiology. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Female. Humans. Paclitaxel / pharmacology. Proto-Oncogene Proteins / metabolism. Tumor Cells, Cultured. Virus Replication. bcl-2-Associated X Protein

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955822.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P0-CA66726-SI
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BAX protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / Viral Proteins; 0 / bcl-2-Associated X Protein; 0 / gamma 34.5 protein, Human herpesvirus 1; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • The clinical and pathologic spectrum of this rare entity, including comparison to other high-grade B-cell neoplasms, has not been well defined.
  • Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology.
  • Nineteen patients were treated with combination chemotherapy, of whom 18 received rituximab and 14 received CNS-directed therapy.
  • Fourteen patients (70%) died within 8 months of diagnosis.
  • DHL is a high-grade B-cell neoplasm with a poor prognosis, resistance to multiagent chemotherapy, and clinical and pathologic features distinct from other high-grade B-cell neoplasms.
  • Familiarity with the morphologic and immunophenotypic spectrum of DHL is important in directing testing to detect concurrent IGH-BCL2 and MYC rearrangements when a karyotype is unavailable.
  • The aggressive clinical behavior and combination of genetic abnormalities seen in these cases may warrant categorization as a separate entity in future classifications and call for novel therapeutic approaches.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


Advertisement
4. Lang K, Lehmann P, Bolsen K, Ruzicka T, Fritsch C: Aminolevulinic acid: pharmacological profile and clinical indication. Expert Opin Investig Drugs; 2001 Jun;10(6):1139-56
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminolevulinic acid: pharmacological profile and clinical indication.
  • The role of aminolevulinic acid hydrochloride (ALA) in photodynamic therapy (PDT) of in situ neoplasias and tumours of epithelial tumours is steadily increasing and it has been shown to be the drug with most clinical use in PDT.
  • In dermatology, topical PDT with ALA is already postulated to be the treatment of choice for actinic keratoses and superficial basal cell carcinomas.
  • In gastroenterology, pulmonology, uro- and nephrology, neurology and gynaecology ALA has an important role as a photosensitiser not only in the diagnosis of neoplastic tissue but as therapy; first experiences have been made with PDT in these organs.
  • Besides the therapeutic efficacy of this technique, the fluorescence of ALA-induced porphyrins can be effectively used to detect and delineate epithelial and endothelial neoplasms.
  • In dermatology, other indications for ALA-treatment are non-tumoural applications, especially psoriasis, viral-induced diseases, or acne vulgaris.
  • ALA is an effective compound in the diagnosis or therapy of various epithelial and endothelial neoplastic lesions.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Aminolevulinic Acid / therapeutic use. Clinical Trials as Topic. Photosensitizing Agents / pharmacology. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / drug therapy. Drug Evaluation / methods. Drug Evaluation / statistics & numerical data. Humans. Photochemotherapy / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11772241.001).
  • [ISSN] 1354-3784
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 105
  •  go-up   go-down


5. Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG: Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med; 2009 Mar;133(3):470-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
  • OBJECTIVES: To describe the morphology of adenocarcinomas responsive to TKIs, compare it to tumors in nonresponding patients, and correlate findings with EGFR mutations, gene copy number, and protein expression.
  • Adenocarcinoma subtypes and morphologic features were defined in histologic and cytologic material.
  • EGFR mutations were detected by sequencing, copy number by chromogenic in situ hybridization, and expression by immunohistochemistry.
  • Nonresponders showed more heterogeneous morphology, higher grade, and more subtypes, and were more likely to show solid growth.
  • Immunohistochemistry and chromogenic in situ hybridization results were not significantly correlated with EGFR mutations or response to TKIs in this study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Mutation. Predictive Value of Tests. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):29-34 [11241263.001]
  • [Cites] Ann Thorac Surg. 2002 Nov;74(5):1640-6; discussion 1646-7 [12440623.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2658-63 [12860941.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):33-40 [14757534.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4227s-4232s [15217963.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):208-12 [15187994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Acta Cytol. 1985 Sep-Oct;29(5):887-94 [2996275.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Diagn Cytopathol. 1997 Mar;16(3):253-7 [9099548.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):109-15 [15386420.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7311-7 [15534107.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):118-22 [15725915.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1265-73 [15712203.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):633-9 [15832087.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3279-87 [15886315.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e17 [15696205.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Med Assoc Thai. 2005 Sep;88 Suppl 4:S322-9 [16623049.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1309-15 [17001163.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):581-7 [17186532.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):741-50 [17238183.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):320-6 [17591931.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • (PMID = 19260752.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121210
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS578987; NLM/ PMC4016915
  •  go-up   go-down


6. Lang K, Schulte KW, Ruzicka T, Fritsch C: Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses. Skin Therapy Lett; 2001 Sep;6(10):1-2, 5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses.
  • The role of photodynamic therapy (PDT) in the treatment of in situ neoplasias and tumors of the skin is steadily increasing.
  • For actinic (solar) keratoses, topical ALA-PDT using Levulan Kerastick (20% topical solution, DUSA Pharmaceuticals) is already postulated to be the treatment of choice.
  • In December 1999, the US FDA approved this topical product for the treatment of actinic keratoses.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685275.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


7. Gonzalez-Cuyar LF, Tavora F, Burke AP, Gocke CD, Zimrin A, Sauk JJ, Zhao XF: Monomorphic post-transplant lymphoproliferative disorder of the tongue: case report and review of literature. Diagn Pathol; 2007;2:49

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monomorphic post-transplant lymphoproliferative disorder of the tongue: case report and review of literature.
  • BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of hematological diseases arising in context of immunosuppression after organ transplantation.
  • METHODS: Using morphologic and immunophenotypic approaches we have studied a case of monomorphic PTLD of the tongue that developed in a patient following unilateral kidney and pancreas transplantation on immunosuppressive therapy.
  • RESULTS: The neoplasm showed large cell morphology and B-cell phenotype.
  • In situ hybridization for Epstein-Barr virus was positive.
  • Complete remission was obtained after decreasing immunosuppressive therapy.
  • CONCLUSION: This rare case increased our awareness of PTLD in the oral cavity of patients following solid organ transplantation and immunosuppressive therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Apr;7(2):431-45 [8468275.001]
  • [Cites] J Heart Lung Transplant. 2005 Jun;24(6):671-9 [15949726.001]
  • [Cites] Nephrology (Carlton). 2006 Aug;11(4):355-66 [16889577.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):e24-8 [16997090.001]
  • [Cites] Am J Hematol. 2007 Mar;82(3):208-14 [17022049.001]
  • [Cites] Curr Drug Targets. 2007 Apr;8(4):533-41 [17430124.001]
  • [Cites] Transplant Proc. 1991 Feb;23(1 Pt 2):1101-3 [1899153.001]
  • [Cites] Mod Pathol. 1989 Nov;2(6):583-92 [2587566.001]
  • [Cites] Lancet. 1967 Jun 3;1(7501):1171-4 [4165129.001]
  • [Cites] Pediatr Transplant. 1999 Nov;3(4):271-81 [10562971.001]
  • [Cites] Transplantation. 1999 Nov 27;68(10):1517-25 [10589949.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1076-88 [11374406.001]
  • [Cites] Laryngoscope. 2001 Jun;111(6):997-1001 [11404611.001]
  • [Cites] Pediatr Transplant. 2001 Jun;5(3):198-203 [11422823.001]
  • [Cites] Hum Pathol. 2001 Nov;32(11):1264-8 [11727268.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):875-8 [12802929.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jul-Aug;65(4):226-9 [14564099.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):103-6 [14662423.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):122-6 [15167049.001]
  • [Cites] J Clin Periodontol. 2004 Jul;31(7):581-5 [15191596.001]
  • [Cites] Clin Infect Dis. 2004 Oct 1;39(7):1016-23 [15472855.001]
  • [Cites] N Engl J Med. 1967 Jul 27;277(4):163-70 [4166031.001]
  • [Cites] Br Med J. 1968 Dec 21;4(5633):746-8 [4881420.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):267-70 [15693799.001]
  • (PMID = 18093326.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2231341
  •  go-up   go-down


8. Fritsch C, Ruzicka T: Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. J Environ Pathol Toxicol Oncol; 2006;25(1-2):425-39
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods.
  • The role of photodynamic therapy (PDT) in the treatment of in situ neoplasias and tumors of the skin is steadily increasing.
  • Aminolevulinic acid (ALA) has been shown to be the drug with most experimental and clinical use in the past.
  • For solar keratoses, topical PDT using MAL is already considered to be the treatment of choice.
  • Epithelial skin tumors such as basal cell carcinomas also respond very well, however, a debulking procedure of the exophytic tumor tissue is an absolute prerequisite to a successful cure.
  • In addition to functioning as a novel therapeutic tool, photodynamic sensitization of skin cancer cells is increasingly used for fluorescence diagnosis (FD) (also known as photodynamic diagnosis or PDD).
  • [MeSH-major] Fluorescence. Photochemotherapy. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Humans. Keratosis / drug therapy. Light. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566733.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 18
  •  go-up   go-down


9. Antoine M: [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment]. Rev Pneumol Clin; 2007 Jun;63(3):183-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment].
  • [Transliterated title] Qu'apporte l'immunohistochimie à la prise en charge du cancer bronchique? De la morphologie au diagnostic et au traitement.
  • The distinction is less clear for large-cell carcinoma or squamous-cell carcinoma, or for tumors with a pleural or mediastinal presentation.
  • IHC is also useful as a diagnostic aid for rare entities: carcinomas with an unusual morphology (alpha-fetoproetin secretors or beta-HCG secretors), melanomas, lymphomas, sarcomas.
  • Finally, IHC contributes to prognosis (proliferation markers, differentiation markers) or prediction of therapeutic response (chemotherapy or targeted therapies).
  • Other morphological techniques such as hybridization in situ or molecular biology techniques will further complete the histological diagnosis in the future.
  • [MeSH-major] Immunohistochemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Chorionic Gonadotropin, beta Subunit, Human / analysis. Forecasting. Humans. Lymph Nodes / pathology. Lymphoma / pathology. Mediastinal Neoplasms / pathology. Melanoma / pathology. Neoplasm Staging. Neuroendocrine Tumors / pathology. Pleural Neoplasms / pathology. Prognosis. Sarcoma / pathology. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675942.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


10. Franklin WA: Pathology of lung cancer. J Thorac Imaging; 2000 Jan;15(1):3-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopic examination of stained smears and tissue sections remains the standard method for definitive diagnosis and classification of lung cancer.
  • However, the morphology of lung cancer is complex, and consensus classifications such as those prepared by a panel World Health Organization (WHO) are required for the sake of consistency and clinical relevance.
  • Expression of these markers is not taken into account in current treatment protocols, and additional correlative studies will be required to determine the clinical relevance of neuroendocrine differentiation in lung carcinoma.
  • In addition to histological classification, microscopic analysis can provide in situ evidence of response to chemotherapy, as well as information on precursor lesions and multistep carcinogenesis in the airways.
  • Finally, it is likely that morphological assessment of lung carcinoma and preneoplastic lesions will continue to be refined as new diagnostic modalities such as spiral computed tomography and fluorescence bronchoscopy provide previously inaccessible specimens for morphological and correlative molecular studies.
  • [MeSH-major] Lung Neoplasms / pathology
  • [MeSH-minor] Algorithms. Diagnosis, Differential. Humans. Immunohistochemistry. Neoplasm Staging. Precancerous Conditions / classification. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10634656.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 34
  •  go-up   go-down


11. Huang YH, Wu QL, Zong YS, Feng YF, Liang JZ, Hou JH, Shao Q, Fu J: Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district. Ai Zheng; 2009 Aug;28(8):805-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was to investigate the clinical presentation, morphologic features, immunophenotype and EBV infection status of sBL in Guangzhou district, a prevalent area of EBV infection.
  • A panel of immunohistochemical staining was performed and EBV-encoded small RNAs (EBERs) in situ hybridization was applied to identify EBV infection.
  • The 2-year survival rate of 15 patients who received chemotherapy or resection plus chemotherapy was 56.00%.
  • Twenty cases showed the prototypic morphology of sBL, and one was the variant of sBL with plasmacytoid differentiation.
  • There were no significant differences in morphology and immunophenotype between EBV-positive and EBV-negative cases.
  • Most patients had lymph node(s) involvement, showing similar morphology and immunophenotype as that of endemic BL.
  • Type I EBV latent infection is associated with 28.57% of cases.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. China. DNA-Binding Proteins / metabolism. Epstein-Barr Virus Nuclear Antigens / metabolism. Female. Follow-Up Studies. Herpesvirus 4, Human / isolation & purification. Humans. Interferon Regulatory Factors / metabolism. L-Lactate Dehydrogenase / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Viral / metabolism. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Epstein-Barr virus encoded RNA 1; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Viral; 0 / interferon regulatory factor-4; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


12. Saika T, Tsushima T, Nasu Y, Arata R, Kaku H, Kusaka N, Kumon H: Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. Jpn J Clin Oncol; 2002 Nov;32(11):461-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
  • OBJECTIVE: The treatment for superficial G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial.
  • PATIENTS AND METHODS: A total of 39 patients with primary superficial bladder cancer (Ta, T1) with G3 components but without concomitant carcinoma in situ (CIS), who had been treated initially with transurethral resection (TUR), were retrospectively analyzed for factors related to tumor recurrence, progression and survival.
  • Initial treatments were TUR alone in 18 patients and TUR with adjuvant therapy (intravesical chemotherapy or BCG therapy) in 21.
  • Factors examined included age, gender, morphology, size and number of tumors and adjuvant therapies.
  • Adjuvant therapies reduced the recurrence rate of the patients with G3.
  • Only tumor morphology, papillary or non-papillary, affected both the progression-free rate and the survival rate of patients with G3.
  • [MeSH-major] Carcinoma in Situ / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12499418.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Haynik DM, Roma AA, Prayson RA: HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):56-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although information is limited, one study suggested that 15% of glioblastoma multiforme (GBM) express HER-2/neu by immunohistochemistry (IHC); gene amplification by fluorescence in situ hybridization (FISH) was not investigated.
  • Studies in this area are potentially significant owing to the role of recombinant monoclonal anti-HER-2/neu antibody traztuzumab (Herceptin) in the treatment of tumors.
  • Thirty-six patients received adjuvant radiation therapy and 19 patients received adjuvant chemotherapy.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857831 for PMID:17536308 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536308.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


14. Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, Pruneri G, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri AJ, Pinotti G, Assanelli A, Scandurra M, Doglioni C, Zucca E, Capella C, Bertoni F: BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol; 2009 May;40(5):645-52
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
  • Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma.
  • Although it is a curable disease, fewer than half of patients are cured with conventional chemotherapy.
  • The highly variable outcome reflects a heterogeneous group of tumors, with different genetic abnormalities and responses to therapy.
  • We analyzed 74 cases of diffuse large B-cell lymphoma using interphase fluorescent in situ hybridization with commercially available probes for split-signal targeting BCL-2, BCL-6, MYC, BCL-10, and MALT-1.
  • Of interest, the presence of chromosome rearrangements was associated with a worse prognosis.
  • The fluorescent in situ hybridization analysis with the panel used in this study is useful to detect the heterogeneity of diffuse large B-cell lymphomas and identify alterations with prognostic implications.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Caspases / genetics. In Situ Hybridization, Fluorescence / methods. Lymphoma, Large B-Cell, Diffuse / genetics. Neoplasm Proteins / genetics. Proto-Oncogene Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Jul;40(7):1055-6; author reply 1056 [19524106.001]
  • (PMID = 19144384.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


15. Vrabie CD, Petrescu A, Waller M: Molecular changes in superficial bladder cancer. Rom J Morphol Embryol; 2007;48(2):131-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For superficial tumors, the aim is to prevent recurrences and progression to an incurable stage, recognizing that surgical removal of the bladder (over treatment for most tumors) is curative up to a point.
  • For more invasive disease, the issue becomes how to determine which tumors can be cured with a single therapy such as surgery, and which, by virtue of a high metastatic potential, requires an integrated systemic approach to achieve cure.
  • For metastatic disease, combination chemotherapy is the standard yet, despite responses in more than 50% of cases, overall cure rates remain low, and progression has been minimal over the past few years.
  • We noticed the antibodies distribution related to stage: carcinoma in situ (Cis or Tis) high percent of p53 (69) and bcl-2 (37.5%).
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Molecular Diagnostic Techniques. Neoplasm Staging. Proto-Oncogene Proteins c-bcl-2 / metabolism. Retinoblastoma Protein / metabolism. Sex Distribution. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641799.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


16. Lock RJ, Virgo PF, Kitchen C, Evely RS: Rapid diagnosis and characterization of acute promyelocytic leukaemia in routine laboratory practice. Clin Lab Haematol; 2004 Apr;26(2):101-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid diagnosis and characterization of acute promyelocytic leukaemia in routine laboratory practice.
  • The rapid diagnosis of the t(15;17)(q22;q21) promyelocytic leukaemia is important in the early introduction of targeted therapy with all-trans retinoic acid plus chemotherapy.
  • We evaluated the use of immunophenotyping, morphology and cytogenetics in our own practice.
  • Cascade testing, using cytoplasmic MPO expression in a high percentage of blast cells in bone marrow as the primary screen and PML (promyelocytic leukaemia protein) expression as the secondary confirmatory test, allowed rapid identification of the cases with t(15;17).
  • This approach allows early instigation of appropriate therapy.
  • [MeSH-major] Antigens, CD / immunology. Antigens, CD13 / immunology. Antigens, Differentiation, Myelomonocytic / immunology. HLA-DR Antigens / immunology. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / immunology. Neoplasm Proteins / immunology. Nuclear Proteins / immunology. Peroxidase / immunology. Transcription Factors / immunology
  • [MeSH-minor] Adult. Bone Marrow / immunology. Child. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Lymphocytes / immunology. Male. Sialic Acid Binding Ig-like Lectin 3. Translocation, Genetic / genetics. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053803.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / HLA-DR Antigens; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human; EC 1.11.1.7 / Peroxidase; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


17. Rao SD, Pagidas K: Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells. Anticancer Res; 2010 Jul;30(7):2519-23
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The MTS assay which measures metabolic activity of cells, bromodeoxyuridine (BrdU) incorporation assay, and flow cytometry were used for the cell proliferation studies and cell morphology, DNA fragmentation analysis and the TUNEL assay for apoptotic effects.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Apoptosis / drug effects. Catechin / analogs & derivatives. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cell Cycle / drug effects. Cell Growth Processes / drug effects. Cell Line, Tumor. Cell Survival / drug effects. DNA, Neoplasm / biosynthesis. Dose-Response Relationship, Drug. Female. Humans. In Situ Nick-End Labeling

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682977.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1-P20RR018728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / DNA, Neoplasm; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


18. Buxant F, Engohan-Aloghe C, Noël JC: Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl Immunohistochem Mol Morphol; 2010 May;18(3):254-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
  • Glucocorticoids (GCs) are used in cancer treatment to induce programmed cell death in transformed cells of the hematopoietic system and to lessen side effects.
  • Moreover, GCs have been described not only as inhibitors of some chemotherapy or radiation-induced apoptosis, but also as inhibitors of cancer progression by down-regulation or up-regulation of different gene expressions.
  • The presence or absence of glucocorticoid receptor (GR) in normal and abnormal breast tissue is thus interesting, and the aim of this study was to analyze the expression of GR during the progression of breast tissue.
  • We tested by immunohistochemistry the expression status of estrogen receptor (ER), progesterone receptor (PR), and GR in normal breast parenchyma (n=49), ductal intraepithelial neoplasia (DIN) 1a (n=9), DIN 1b-1c (n=15), DIN 2-3 (n=21), and invasive breast carcinoma (n=39).
  • Understanding the role of GCs in breast carcinoma is thus essential before continuing the widespread use of GCs combined with antineoplastic drugs or agents in the clinical management of women with breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875955.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Glucocorticoid; 0 / Receptors, Progesterone
  •  go-up   go-down


19. Oh SH, Park TS, Kim HH, Chang CL, Lee EY, Son HC, Chung JS, Cho GJ: Tetraploid acute promyelocytic leukemia with double t(15;17) and PML/RARA rearrangements detected by fluorescence in situ hybridization analysis. Cancer Genet Cytogenet; 2003 Aug;145(1):49-53
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetraploid acute promyelocytic leukemia with double t(15;17) and PML/RARA rearrangements detected by fluorescence in situ hybridization analysis.
  • Acute promyelocytic leukemia (APL) is characterized by a serious hemorrhagic syndrome, unique morphologic findings, and its response to retinoids.
  • Tetraploidy is a very rare chromosomal abnormality in acute myelocytic leukemia.
  • This report presents a unique case of APL with a tetraploid clone characterized by two t(15;17) without other chromosomal changes, as well as PML/RARA rearrangements confirmed fluorescence in situ hybridization.
  • The morphology of the blast cells was that of the classic M3 subtype, but the mean blast size exceeded that of control APL cases with diploidy.
  • Despite all-trans-retinoic acid (ATRA) treatment and chemotherapy, leukemic cells persisted in the blood, and the patient died of an intracranial hemorrhage on the 16th day after admission.
  • [MeSH-major] Aneuploidy. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Leukemia, Promyelocytic, Acute / genetics. Neoplasm Proteins / genetics. Nuclear Proteins. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Translocation, Genetic
  • [MeSH-minor] Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Middle Aged. Oncogene Proteins, Fusion / genetics. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12885462.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human
  •  go-up   go-down


20. Lee DS, Lee YS, Kim YR, Han KS, Park KU, She CJ, Kim EC, Park SY, Cho HI: RARA fluorescence in situ hybridization overcomes the drawback of PML/RARA fluorescence in situ hybridization in follow-up of acute promyelocytic leukemia. Cancer Genet Cytogenet; 2002 Dec;139(2):104-8
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RARA fluorescence in situ hybridization overcomes the drawback of PML/RARA fluorescence in situ hybridization in follow-up of acute promyelocytic leukemia.
  • Determination of the remission of acute promyelocytic leukemia (APL) after chemotherapy can be difficult because many cases of APL show reverse transcription polymerase chain reaction positivity after consolidation treatment.
  • Moreover, the discrimination of leukemic promyelocytes and regenerating promyelocytes by morphology is sometimes difficult.
  • Although PML/RARA fluorescence in situ hybridization (FISH) can help, the major drawback of FISH is its high false positive rate, which reaches up to 5-10%.
  • We used RARA FISH at the initial diagnosis (16 cases) and follow-up of APL patients (21 cases) with t(15;17), though RARA FISH was originally designed to detect translocations involving the RARA gene rather than t(15;17), and compared the results with those of PML/RARA FISH.
  • In conclusion, we believe that once the PML/RARA rearrangement is confirmed either by G-banding or FISH, RARA FISH is more effective than PML/RARA during the follow-up of APL after treatment.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 15 / ultrastructure. Chromosomes, Human, Pair 17 / ultrastructure. In Situ Hybridization, Fluorescence / methods. Leukemia, Promyelocytic, Acute / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Receptors, Retinoic Acid / genetics. Translocation, Genetic
  • [MeSH-minor] Blood Cells / ultrastructure. Bone Marrow Cells / ultrastructure. Disease Progression. False Positive Reactions. Follow-Up Studies. Humans. Neoplasm, Residual. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12550769.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Retinoic Acid; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 0 / retinoic acid receptor alpha
  •  go-up   go-down


21. Chen B, Roskams T, Xu Y, Agostinis P, de Witte PA: Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int J Cancer; 2002 Mar 10;98(2):284-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model.
  • The mechanism of tumor eradication and mode of cell death induced by in vivo photodynamic therapy (PDT) with hypericin were investigated in the present study using 2 therapeutic protocols.
  • A significant reduction in tumor perfusion, as determined by the retention of fluorescein in the tumor tissue, was detected immediately after both PDT treatments.
  • Further decrease in tumor perfusion was observed in the hours after treatment.
  • The kinetics of tumor cell survival estimated by the in vivo/in vitro clonogenic assay revealed no or limited cell death when tumors were explanted immediately after irradiation, whereas a delayed but progressive cell death was detected when tumors remained in situ after both PDT treatments.
  • The detection of nucleosomal DNA fragmentation by agarose gel electrophoresis or TUNEL assay and the assessment of cell morphology by light microscopy indicated that apoptosis was the most prominent tumor response to hypericin-mediated PDT.
  • Furthermore, immunohistochemical analysis of the tumor tissue showed an increased expression of both Fas and Fas ligand after irradiation, suggesting that this cell death pathway might contribute to the overall PDT-induced apoptotic response.
  • [MeSH-minor] Animals. Antigens, CD95 / biosynthesis. Blood Vessels / pathology. Cell Nucleus / ultrastructure. Cell Survival / drug effects. DNA Fragmentation. Dose-Response Relationship, Radiation. Fas Ligand Protein. Female. In Situ Nick-End Labeling. Kinetics. Membrane Glycoproteins / biosynthesis. Mice. Mice, Inbred C3H. Microscopy, Fluorescence. Neoplasm Transplantation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PERYLENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11857421.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Membrane Glycoproteins; 0 / Photosensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


22. Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, Sneige N, Gilcrease MZ: Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol; 2005 Nov;29(11):1456-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metaplastic carcinomas of the breast are a heterogeneous group of neoplasms ranging from tumors with a predominant component of overt carcinoma and focal mesenchymal differentiation to keratin-positive tumors with pure sarcomatoid morphology.
  • Anderson Cancer Center with metaplastic carcinoma of the breast with pure or almost pure sarcomatoid morphology.
  • Patients were included in the study if their tumors had sarcomatoid morphology and:.
  • 1) an invasive carcinomatous component identifiable on hematoxylin and eosin stains comprising less than 5% of the invasive tumor; or 2) associated ductal carcinoma in situ; or 3) immunohistochemical expression of keratin in the sarcomatoid areas.
  • Patients with low-grade fibromatosis-like metaplastic tumors and those who received neoadjuvant chemotherapy were excluded.
  • Ten patients experienced local relapse, including 7 of 11 patients treated with breast-conserving surgery, and 9 developed distant metastases, most frequently to the lungs.
  • In addition to systemic treatment, early aggressive local therapy is recommended, as these patients have a high rate of local relapse.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Female. Humans. Mastectomy. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Aug;30(8):1052-3; author reply 1053-5 [16861980.001]
  • (PMID = 16224212.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Gurski LA, Jha AK, Zhang C, Jia X, Farach-Carson MC: Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials; 2009 Oct;30(30):6076-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells.
  • The current investigation aimed to develop a biomimetic, three-dimensional (3D) culture system for poorly adherent bone metastatic prostate cancer cells (C4-2B) for use as an in vitro platform for anti-cancer drug screening.
  • In situ encapsulation of C4-2B cells was achieved by simple mixing of HAALD and HAADH in the presence of the cells.
  • Unlike two-dimensional (2D) monolayer culture in which cells adopt an atypical spread morphology, cells residing in the HA matrix formed distinct clustered structures which grew and merged, reminiscent of real tumors.
  • Anti-cancer drugs added to the media surrounding the cell/gel construct diffused into the gel and killed the embedded cells.
  • The HA hydrogel system was used successfully to test the efficacy of anti-cancer drugs including camptothecin, docetaxel, and rapamycin, alone and in combination, including specificity, dose and time responses.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDRAZINE SULFATE .
  • Hazardous Substances Data Bank. HYDRAZINE .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nat Prod. 2004 Feb;67(2):232-44 [14987065.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29420-34 [12748184.001]
  • [Cites] Biomaterials. 2004 Aug;25(19):4797-804 [15120526.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2) [10881018.001]
  • [Cites] Int J Pharm. 2001 Feb 1;213(1-2):25-9 [11165091.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):103-19 [15246682.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2169-77 [15330157.001]
  • [Cites] Ann N Y Acad Sci. 1995 Dec 29;770:70-8 [8597383.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Jan 18;9(2):295-300 [10021948.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2891-7 [10383151.001]
  • [Cites] Fed Proc. 1958 Dec;17(4):1075-7 [13619775.001]
  • [Cites] Int J Pharm. 2004 Dec 9;287(1-2):13-9 [15541907.001]
  • [Cites] Biomacromolecules. 2005 Mar-Apr;6(2):1132-9 [15762686.001]
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):365-77 [15975824.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20 [16606824.001]
  • [Cites] Acta Histochem. 2006;108(2):141-7 [16713618.001]
  • [Cites] J Natl Cancer Inst. 2006 Aug 16;98(16):1118-28 [16912264.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):813-23 [16990858.001]
  • [Cites] Biomacromolecules. 2006 Dec;7(12):3336-44 [17154461.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2006 Sep-Oct;42(8-9):242-7 [17163781.001]
  • [Cites] Front Biosci. 2007;12:3273-86 [17485298.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jun;6(6):455-63 [17541418.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3109-14 [17545512.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):373-400 [17431753.001]
  • [Cites] Cell. 2007 Aug 24;130(4):601-10 [17719539.001]
  • [Cites] Nat Methods. 2007 Oct;4(10):855-60 [17767164.001]
  • [Cites] Biotechnol Adv. 2007 Nov-Dec;25(6):537-57 [17716848.001]
  • [Cites] Acc Chem Res. 2008 Jan;41(1):139-48 [17655274.001]
  • [Cites] Acta Biomater. 2008 Mar;4(2):256-63 [17936097.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e7 [18321396.001]
  • [Cites] J Control Release. 2008 May 8;127(3):231-8 [18384903.001]
  • [Cites] Prostate. 2008 Jun 1;68(8):861-71 [18361409.001]
  • [Cites] Semin Cancer Biol. 2008 Aug;18(4):244-50 [18534864.001]
  • [Cites] J Control Release. 2008 Jul 14;129(2):144-50 [18538885.001]
  • [Cites] Expert Opin Pharmacother. 2008 Aug;9(11):1969-79 [18627334.001]
  • [Cites] Matrix Biol. 2008 Jul;27(6):573-85 [18411046.001]
  • [Cites] Mol Pharm. 2008 Sep-Oct;5(5):849-62 [18680382.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):1027-36 [19218337.001]
  • [Cites] J Cell Biochem. 2009 Jun 1;107(3):473-81 [19347904.001]
  • [Cites] FEBS Lett. 2002 Sep 25;528(1-3):101-8 [12297287.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39703-12 [12145287.001]
  • [ErratumIn] Biomaterials. 2010 May;31(14):4248
  • (PMID = 19695694.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / R01 DC008965-03S2; United States / NCRR NIH HHS / RR / P20 RR016472-09; United States / NCI NIH HHS / CA / P01 CA098912; United States / NCI NIH HHS / CA / CA098912-01A10002; United States / NIDCD NIH HHS / DC / R01DC008965; United States / NCRR NIH HHS / RR / P20 RR016472; United States / NIDCD NIH HHS / DC / R01 DC008965; United States / NCI NIH HHS / CA / P01 CA098912-01A10002; None / None / / P20 RR016472-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / Hydrogels; 25852-47-5 / Hydrogel; 27RFH0GB4R / hydrazine; 9004-61-9 / Hyaluronic Acid
  • [Other-IDs] NLM/ NIHMS136391; NLM/ PMC2782556
  •  go-up   go-down


24. Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S: c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res; 2007 Apr 15;13(8):2369-77
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To correlate morphologic changes with molecular, biochemical, and cytogenetic profiles in gastrointestinal stromal tumor (GIST) patients before and after imatinib treatment.
  • EXPERIMENTAL DESIGN: We investigated 132 tumor samples obtained from 35 patients with advanced disease who underwent resective surgery after imatinib treatment according to the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group protocol.
  • On the basis of imaging findings, 27 patients were responders and 8 progressors, and retaining this radiological subdivision, we analyzed posttreatment morphologic changes correlating them with molecular, biochemical, and cytogenetic analyses.
  • RESULTS: On the basis of morphology (residual viable cellularity/proliferation markers), three subgroups were identified showing high, moderate, or low response.
  • The correlation between morphology and the molecular findings showed that secondary mutations segregated with the low-response subgroup, whereas c-Kit primary resistance mutations were randomly distributed in the three subgroups.
  • Fluorescence in situ hybridization analysis of c-Kit/PDGFRA genes showed that all of the progressing cases were disomic.
  • Referring to morphology, among the responding cases, a disomic pattern was mainly restricted to the high responders, whereas the moderate and low responders were aneusomic.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / genetics. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Benzamides. Combined Modality Therapy. Follow-Up Studies. Humans. Imatinib Mesylate. Immunophenotyping. In Situ Hybridization, Fluorescence. Mitosis. Mutation

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438095.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


25. Gilaberte M, Gallardo F, Bellosillo B, Saballs P, Barranco C, Serrano S, Pujol RM: Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma. Br J Dermatol; 2005 Oct;153(4):828-32
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is characterized by immunoblastic morphology and plasma cell phenotype.
  • We report a 44-year-old man with AIDS and Kaposi sarcoma (KS) previously treated with doxorubicin who, following treatment with highly active antiretroviral therapy, developed an erythematous infiltrated nodule on the right arm.
  • Epstein-Barr virus (EBV) mRNA was detected by in situ hybridization within the plasmablastic cells.
  • Two years later an infiltrated plaque developed on the abdominal wall.
  • PBL may be seen in patients with transplants or receiving chemotherapy, but is usually observed in patients with advanced AIDS.
  • [MeSH-minor] Adult. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Neoplasm Regression, Spontaneous. Recurrence

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181470.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Rudzki Z, Rucińska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczyk M, Włodarska I, Stachura J: ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol; 2005;56(1):37-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 48-year old man presented with a large upper neck mass growing slowly over 18 months.
  • At the diagnosis the patient manifested with the stage IIIB.
  • The patient died of massive bleeding from his decomposing tumor 3 months after the diagnosis.
  • The tumor showed immunoblastic/anaplastic morphology, with some Reed-Sternberg-like cells positive for ALK.
  • The patient (stage IVB) currently undergoes chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / metabolism. Cyclophosphamide / administration & dosage. DNA, Neoplasm / analysis. Doxorubicin / administration & dosage. Fatal Outcome. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Receptor Protein-Tyrosine Kinases. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921012.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


27. Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner K, Chott A, Jaeger U: Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia; 2004 Jan;18(1):146-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To define reproducible criteria for subgroups of diffuse large B-cell lymphomas (DLBCL), including lymphomas with plasmablastic/plasmacytoid features (PB/PC-Fs), we investigated 66 DLBCL; the samples were categorized as either centroblastic (CB), immunoblastic (IB) or PB/PC-F applying standardized morphologic criteria.
  • Immunoglobulin-V(H) gene mutation analysis was consistent with a germinal or postgerminal center-cell origin.
  • By fluorescence in situ hybridization analysis, 11/13 (85%) PB/PC-F had a monoallelic TP53 deletion.
  • Importantly, PB/PC-F were resistant to standard chemotherapy (complete remission rate 47%, relapse rate 71%) and even autologous stem-cell transplantation.
  • Our data indicate a strong association of plasmablastic/plasmacytoid morphology with TP53 deletions, poor response to chemotherapy and short survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / analysis. Female. Follow-Up Studies. Genes, Immunoglobulin. Germinal Center / immunology. Herpesvirus 4, Human / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Lymphoma, Large-Cell, Immunoblastic / classification. Lymphoma, Large-Cell, Immunoblastic / mortality. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Prognosis. RNA, Viral / genetics. Sequence Deletion. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14603341.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / RNA, Viral
  •  go-up   go-down


28. Paner GP, McKenney JK, Epstein JI, Amin MB: Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma. Am J Surg Pathol; 2008 Jul;32(7):1022-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
  • Rhabdomyosarcoma (RMS) represents the most common malignant soft tissue tumor in children and adolescents with the urinary bladder representing a frequent site.
  • We report the clinicopathologic features of 5 bladder neoplasms with rhabdomyosarcomatous differentiation in adults and emphasize the differential diagnosis in the adult setting.
  • Microscopically, all tumors had a primitive undifferentiated morphology with cells containing scant cytoplasm, varying round to fusiform nuclei with even chromatin distribution, and frequent mitoses.
  • The degree of morphologic overlap with small cell carcinoma of the bladder, a relatively more common round cell tumor in adults, was striking.
  • No other case had previous history of bladder cancer or concurrent carcinoma in situ or invasive urothelial carcinoma.
  • Two patients received chemotherapy, 2 underwent cystectomy, and 1 had transurethral resection alone.
  • In conclusion, (1) RMS of the urinary bladder in adults more commonly presents as a primitive round blue cell neoplasm that has significant morphologic and immunohistochemical overlap with small cell carcinoma of the bladder. (2) Although RMS in children generally have a botryoid embryonal histology with favorable outcome, bladder RMS in adults frequently demonstrates alveolar or unclassified histology, commonly with anaplasia, and have a uniformly aggressive clinical course.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Rhabdomyosarcoma, Alveolar / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anaplasia. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. MyoD Protein / analysis. Myogenin / analysis. Synaptophysin / analysis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469707.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin; 0 / Synaptophysin
  •  go-up   go-down


29. Barni S, Pontiggia E, Bertone V, Pontiggia P, Mathé G: Analysis of cell proliferation and cell death during in situ hyperthermic treatment of neoplastic cells: a case report of human non-Hodgkin lymphoma. Biomed Pharmacother; 2006 Jun;60(5):227-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of cell proliferation and cell death during in situ hyperthermic treatment of neoplastic cells: a case report of human non-Hodgkin lymphoma.
  • In this study we observed the effects in vivo of hyperthermic treatment on the cell kinetics (cell proliferation/cell death) in one case of human non-Hodgkin lymphoma, by analyzing the following morpho-cytochemical parameters: Acridine Orange fluorochromasia, mitotic index, proliferating cell nuclear antigen (PCNA) expression, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) labeling, and ultrastructure morphology.
  • The data indicates that the hyperthermic treatments limit the cell proliferation (e.g. arrest and/or deceleration of the cell cycle) by facilitating the trigger of programmed cell death.
  • It was concluded that thermal injury can be considered an effective inducer of antiproliferative and apoptogenic associated effects on the growth of this kind of neoplasia.
  • [MeSH-major] Hyperthermia, Induced. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Count. Cell Death / drug effects. Cell Proliferation / drug effects. Combined Modality Therapy. DNA Fragmentation. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Kinetics. Male. Microscopy, Electron, Transmission. Microscopy, Fluorescence. Middle Aged. Mitosis / drug effects. Neoplasm Recurrence, Local. Proliferating Cell Nuclear Antigen / metabolism. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757146.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Neoplasm
  •  go-up   go-down


30. Carter MR, Hornick JL, Lester S, Fletcher CD: Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol; 2006 Mar;30(3):300-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because the term "metaplastic carcinoma" comprises a heterogeneous group of tumors, it has been difficult to reliably predict biologic potential or to determine optimal therapy.
  • Treatment was by excision and/or mastectomy with axillary node evaluation in most cases, often combined with postoperative radiation and/or chemotherapy.
  • All cases were clinically of breast origin, showed >or=80% spindled/sarcomatoid morphology, and demonstrated keratin positivity and/or close association with ductal carcinoma in situ.
  • Twenty-seven cases exhibited pure spindled or sarcomatoid morphology of variable appearance and nuclear grade, whereas 2 contained high-grade invasive ductal carcinoma comprising <or=20% of the tumor mass.
  • Two cases exhibited heterologous elements (1 rhabdomyosarcoma and 1 with both chondrosarcoma and osteosarcoma) and 4 were associated with ductal carcinoma in situ.
  • Of 20 cases in which axillary nodes were biopsied, definitive nodal metastases were identified in only 1 (5%), and this was in a case with a significant component of invasive ductal carcinoma.
  • Three patients developed local recurrences.
  • Based on this series, spindle cell/sarcomatoid carcinoma of the breast is a highly aggressive neoplasm with a high rate of extranodal metastases.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Sarcoma / metabolism. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2007 Feb;31(2):326-7; author reply 327 [17255781.001]
  • (PMID = 16538049.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


31. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer; 2003 Mar 1;97(5):1276-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients who have oligodendrogliomas (OD) that demonstrate loss of both 1p and 19q appear to have a better prognosis after they receive chemotherapy and radiotherapy compared with patients who have OD without these characteristics.
  • It is unclear whether this improvement in outcome is due only to a better response to treatment.
  • The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy.
  • METHODS: The initial presentation, prior treatments, overall survival, and response to chemotherapy were assessed.
  • The 1p and 19q status in OD lesions was determined with fluorescence in situ hybridization on paraffin embedded, archival material using locus specific probes.
  • RESULTS: Patients who had OD lesions with a combined loss of 1p and 19q typically presented with low-grade tumors that manifested with seizures of long-standing duration.
  • In contrast, patients who had OD lesions without a combined loss of 1p and 19q usually presented with focal deficits that required immediate treatment.
  • Both the response rate to chemotherapy and the time to disease progression after chemotherapy were significantly better in patients who had a combined loss of 1p and 19.
  • Tumors with classic OD morphology more often had a combined loss of 1p and 19q, although the genotype was better at identifying patients with chemoresponsive tumors.
  • Future trials must keep these tumor types apart.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Genes, p53. Oligodendroglioma / genetics
  • [MeSH-minor] Disease Progression. Humans. In Situ Hybridization, Fluorescence. Lomustine / administration & dosage. Mutation. Neoplasm Recurrence, Local. Procarbazine / administration & dosage. Survival Analysis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12599236.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


32. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res; 2000 Aug 4;87(3):214-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modulation of angiogenesis is now a recognized strategy for the prevention and treatment of pathologies categorized by their reliance on a vascular supply.
  • Analysis of nuclear morphology, DNA integrity, and enzymatic in situ labeling of apoptosis-induced strand breaks demonstrated that this regression was due to the induction of apoptosis specifically within the sprouting cell population.
  • Treatment with 1,25(OH)(2)D(3) (12.5 pmol/d for 8 weeks) produced tumors that were less well vascularized than tumors formed in mice treated with vehicle alone.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Calcitriol / pharmacology. Neovascularization, Physiologic / drug effects
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Breast Neoplasms / pathology. Cattle. Cell Division / drug effects. Cells, Cultured / drug effects. Endothelial Growth Factors / antagonists & inhibitors. Endothelial Growth Factors / pharmacology. Endothelium, Vascular / cytology. Endothelium, Vascular / drug effects. Female. Lymphokines / antagonists & inhibitors. Lymphokines / pharmacology. Mice. Mice, Inbred BALB C. Mice, Nude. Morphogenesis / drug effects. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Transplantation, Heterologous. Tumor Cells, Cultured / transplantation. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10926872.001).
  • [ISSN] 0009-7330
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; FXC9231JVH / Calcitriol
  •  go-up   go-down






Advertisement